– Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
– Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
– Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
– Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Voir le communiqué de presse SYMETIS